ArticleInternational journal of genomics2026
Single-Cell RNA-seq Reveals Deubiquitination Genes as Prognostic Markers in Hepatocellular Carcinoma.
Article in International journal of genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Single-Cell RNA-seq Reveals Deubiquitination Genes as Prognostic Markers in Hepatocellular Carcinoma.International journal of genomics · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) carries a dismal prognosis, yet the contribution of deubiquitination-an essential posttranslational regulator-to its progression remains poorly defined. Methods: Single-cell RNA-seq profiles of 13 treatment-naïve HCC tumors were integrated with 374 TCGA and 243 ICGC bulk RNA-seq cohorts. Deubiquitinase (DUB) activity was quantified per cell with AUCell; pathway enrichment was performed with clusterProfiler. A LASSO-Cox machine learning pipeline was used to build a DUB-based risk signature, which was cross-validated internally and externally by time-dependent ROC analysis. Results: Malignant cells exhibited divergent DUB transcription relative to immune compartments (myeloid, B). DUB-high neoplastic subsets displayed heightened inflammatory and IFN- Conclusions: This study highlights the role of deubiquitination in HCC progression and its potential as a prognostic biomarker. The developed model could serve as a valuable tool for patient stratification and personalized treatment strategies, although further experimental validation is needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.